Vera Therapeutics, Inc. (VERA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Below-average business quality.
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN, with a BLA granted Priority Review (PDUFA July 7, 2026), plus MAU868 for BK viremia and VT-109 (preclinical). No products approved; $714.6M cash as of December... Read more
Sell if holding. Engine safety override at $33.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Vera Therapeutics, Inc.
Latest news
- Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91 — benzinga May 15, 2026 positive
- Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate — benzinga May 7, 2026 negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $31.83. Score 4.8/10, moderate confidence.
Take-profit target: $68.11 (+104.8% upside). Prior stop was $31.83. Stop-loss: $31.83.
Quality below floor (1.6 < 4.0).
Vera Therapeutics, Inc. trades at a P/E of N/A (forward -9.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover VERA with a consensus score of 4.3/5. Average price target: $78.
What does Vera Therapeutics, Inc. do?Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN,...
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc dual BAFF/APRIL inhibitor) for IgAN, with a BLA granted Priority Review (PDUFA July 7, 2026), plus MAU868 for BK viremia and VT-109 (preclinical). No products approved; $714.6M cash as of December 31, 2025. Atacicept is in-licensed from Ares Trading S.A. with worldwide commercialization rights.